Analyst activity on Monday tilted bullish for Moderna and defence names, while chipmaker AMD faced a target trim.
MRNA received a target price increase, with consensus now sitting at $118.59, up from $116.50. The stock carries short interest of 13.4% of free float — the highest among this batch — suggesting bears remain sceptical. A rising analyst target alongside heavy shorting can set up a squeeze.
AMD saw its average target dip to $612.62 from $613.84. The cut is modest, but it breaks from a streak of positive revisions. AMD's $779 billion market cap means even small target shifts move a lot of notional value.
Eaton Corporation earned a consensus upgrade, pushing buy-side coverage from 22 to 23 analysts. The power management firm continues to benefit from electrification and data centre spending tailwinds.
General Dynamics also attracted a target lift to $421.68 from $420.02. Defence budgets remain elevated globally. Analysts appear comfortable adding to targets.
HOOD lost a recommendation in the latest round. Its consensus buy count still sits at 23. At a $96.5 billion market cap, it remains one of the pricier fintech valuations. Short interest of just 4.1% of free float suggests shorts aren't piling in despite the lost coverage.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
